AnazaoHealth is a specialty pharmacy that has been in the compounding business for over 25 years. Patient safety is and has always been our primary concern.
AnazaoHealth’s 503A compounding pharmacy in Tampa, FL focuses on patient-specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials. The pharmacy is appropriately licensed in all fifty states, the District of Columbia, and selected U.S. territories.
We have a quality oversight program that we believe is a compounding pharmacy industry leader. This oversight program allows us to meet or exceed all USP <797> sterile compounding and USP <795> non-sterile compounding standards. In addition to the USP compounding standards, we perform both internal and external audits to validate our quality assurance processes. Our sterile compounding process involves no fewer than four different validation checks prior to completion of an order and makes extensive use of bar code technology, reducing chance of human error.
In 2014, AnazaoHealth, Las Vegas registered with the FDA as a 503B Outsourcing Facility. Outsourcing Facilities are required to comply with Section 503B of the FD&C Act and the corresponding guidance set forth by the FDA (Current Good Manufacturing Practice - Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act). The cGMP guidance requires proper design, monitoring, and control of manufacturing processes and facilities, and ensures that products are made with a higher-level of quality than what is required by USP <797>.
We have developed a culture that is focused on the quality of products produced. Each person is accountable for maintaining a high level of quality throughout the process.
Our Las Vegas facility is inspected by the FDA and has implemented a quality system that assures products manufactured meet the highest quality standards. AnazaoHealth, Las Vegas is licensed appropriately to ship office use products to most states, the District of Columbia, and selected U.S. territories. In Alabama and North Dakota, Patient Specific Prescriptions Only.